BMJ Best Practice

Long QT syndrome

Straight to the point of care

Last updated: Aug 29, 2023

Table of Contents

Summary

Long QT syndrome (LQTS) is characterized by a prolonged QT interval on ECG, which may be congenital or acquired.

In congenital LQTS, genetic mutations affect ion channels important in myocardial repolarization.

Acquired LQTS may occur secondary to ingestion of QT interval-prolonging drugs, electrolyte imbalances, or bradyarrhythmias.

Patients with LQTS are at increased risk of syncope, ventricular arrhythmias (including torsades de pointes), and sudden cardiac death.

Unless there is an identifiable reversible cause, treatment primarily involves lifestyle modification and beta-blocker therapy with the implantation of a cardioverter-defibrillator in selected cases.

Definition

Long QT syndrome (LQTS) is a congenital or acquired condition that is characterized by a prolonged QT interval on the surface ECG and is associated with a high risk of sudden cardiac death due to ventricular tachyarrhythmias. In congenital LQTS, mutations within 17 identified genes result in a variety of channelopathies affecting myocardial repolarization, thus prolonging the QT interval.

Published definitions of the normal QT interval vary. A prolonged QT interval is defined as a heart rate-corrected QT interval (QTc) of >450 ms in males and >460 ms in females.[1] The European Society of Cardiology suggests using a QTc of ≥480 ms for diagnosing LQTS and using a QTc of 460-479 as a borderline range where a diagnosis may be considered along with other criteria.[2]

Epidemiology

Historically, only the most severe cases of LQTS were detected and reported, suggesting that the condition was extremely rare.[9] However, it is currently estimated that at least 1 in 2000 to 1 in 2500 people worldwide are affected with congenital LQTS, although its observed prevalence has increased as awareness and screening for the condition has improved.[4] [5] [11] Untreated LQTS has an annual rate of sudden cardiac death of <0.5% in asymptomatic patients, which rises to approximately 5% in patients who have a history of syncope.[2] LQTS is thought to be responsible for approximately 3000 sudden deaths in the US annually.[11] [12] [13] [14] The 10-year mortality rate in untreated, symptomatic index cases is approximately 50%.[5]

The mean age of patients at presentation is 14 years.[2] Few data are available to suggest worldwide racial or ethnic variation in prevalence, but this has not been widely studied. LQTS is more commonly diagnosed in women, which may be a spurious observation resulting from the higher upper limit for the corrected QT interval (QTc) in postpubertal females than in males (460 ms and 450 ms, respectively), although one report suggests a slightly higher incidence in women on the basis of genetics.[15] About 70% to 85% of patients with LQTS have an identifiable genetic mutation.[2] [5] The LQT1, LQT2, and LQT3 subtypes of the condition constitute over 90% of cases for which a gene can be identified, with LQT4 to LQT15 accounting for the remainder. KCNQ1 mutations, which lead to LQT1, account for up to 35% to 45% of genotyped patients and are the most commonly identified mutations in these patients, followed by KCNH2 mutations, which lead to LQT2.[16] Romano-Ward syndrome is the most common form of LQTS and has an autosomal dominant form of inheritance, as opposed to the Jervell and Lange-Nielsen syndrome, which is a rare autosomal recessive form of LQTS.[8]

The overall incidence and prevalence of acquired LQTS is not known and is difficult to estimate. In one retrospective review of hospital admissions, 0.7% of patients had a corrected QT interval >500 ms.[17] In another case-control study from a cohort of hospitalized cancer patients, 1.5% had a corrected QT interval >500 ms.[18]

Etiology

Genetic mutations identified in 17 genes account for congenital LQTS, with those in the following 3 genes constituting 90% to 95% of cases where a gene can be identified.[3] [5] [8] [16] [19] [20]

- LQT1 arises from loss-of-function mutations in the KCNQ1 gene, which encodes a potassium channel responsible for the slow component of the delayed rectifier current (IKs). A homozygous mutation in KCNQ1 results in the autosomal recessive Jervell and Lange-Nielsen syndrome (JLNS).
- LQT2 arises from loss-of-function mutations in the KCNH2 gene, which encodes a potassium channel responsible for the rapid component of the delayed rectifier current (IKr).
- LQT3 arises from gain-of-function mutations in the SCN5A gene, which encodes a sodium channel.

While the number of genes implicated in causing LQTS has expanded to 17, some have limited or disputed evidence casting doubt on their association with disease.[7]

Acquired LQTS results from a wide variety of causative factors:

- Some of the drugs known to prolong the QT interval or cause depletion of potassium and/or magnesium are quinidine, procainamide, sotalol, amiodarone, disopyramide, dofetilide, phenothiazines, tricyclic antidepressants, and methadone.[21] [22] [Credible Meds (Arizona CERT): drugs that prolong the QT interval] (https://crediblemeds.org/index.php/login/dlcheck) Certain cancer

treatments are also known to cause QT prolongation, e.g., kinase inhibitors, growth factor inhibitors, androgen-deprivation therapies, and chimeric antigen receptor T-cell therapies.[23] [24]
- Electrolyte imbalances: in particular hypokalemia, hypomagnesemia, and hypocalcemia.
- Bradyarrhythmias: any sudden bradycardia or atrioventricular (AV) nodal block may result in QT prolongation or pause-dependent QT prolongation.
- Central nervous system (CNS) lesions: such as intracranial hemorrhage (especially subarachnoid hemorrhage) and ischemic strokes.
- Malnutrition: liquid protein diet, starvation.
- Intense exercise training may be a cause of reversible long QT interval in athletes.[25]

Pathophysiology

In congenital LQTS, a number of identified genetic mutations cause the alteration of a specific ion channel current, leading to the pathophysiologic prolongation of repolarization, which equates to QT interval prolongation on the ECG.

In LQT1 and LQT2, mutations reduce function of the delayed rectifier potassium currents (IKs and IKr, respectively), which shuttle potassium ions out of the myocardial cell during repolarization, thus making the cell more negative and returning it to the baseline state of approximately -90 mV.

- LQT1 results from heterozygous loss-of-function mutations in the KCNQ1 gene, which encodes the alpha subunit of the slow-activating potassium channel responsible for the slow component of IKs. These mutations lead to dysfunctional IKs channels, which in turn lead to dispersion of repolarization from the epicardial to the endocardial surface, allowing potential development of ventricular tachyarrhythmias. Electrocardiographically, there are characteristic prolonged QT intervals associated with a broad-based T wave.[16]



ECG findings in type 1 long QT syndrome

From the collection of Dr James P. Daubert

- LQT2 results from mutations in the KCNH2 gene, which encodes the alpha (HERG) subunit of the potassium channel responsible for the rapid component of IKr. These mutations lead to dysfunctional IKr channels, which in turn lead to slowed repolarization and transmural dispersion of repolarization. This predisposes to ventricular tachyarrhythmias, particularly torsades de pointes. Electrocardiographically, there are characteristic low-amplitude and notched T waves.[16]



ECG findings in type 2 long QT syndrome

From the collection of Dr James P. Daubert

- LQT3 results from mutations in the SCN5A gene, which encodes for rapidly inactivating sodium channels, resulting in a gain of function of a late sodium current allowing an inward flow of sodium

ions to persist long into the plateau phase of the action potential, thereby prolonging repolarization. Electrocardiographically, there are characteristic long ST segments with a late-appearing T wave resulting in a long QT interval.[16]



ECG findings in type 3 long QT syndrome

From the collection of Dr James P. Daubert

- A hereditary form of complete AV block resulting from degeneration of the bundle of His and its branches has been linked to the SCN5A gene (mutations of which are responsible for LQT3), which encodes for rapidly inactivating sodium channels, resulting in a gain of function of a late sodium current allowing an inward flow of sodium ions to persist long into the plateau phase of the action potential, thereby prolonging repolarization.

The many causes of acquired LQTS result in prolongation of the QT interval through a variety of pathophysiologic mechanisms.[26]

- Hypokalemia causes hyperpolarization of myocardial cell membranes with consequent prolongation of repolarization, which equates to QT interval prolongation on the ECG.
- Hypomagnesemia, which often coexists with hypokalemia, causes early afterdepolarizations, which in turn lead to prolonged repolarization of myocardial cells and subsequent QT interval prolongation on the ECG.
- Hypocalcemia prolongs the plateau phase of the action potential, thereby prolonging repolarization of myocardial cells, which equates to prolongation of the QT interval on the ECG.

The likelihood of developing acquired LQTS is influenced by genetic variants that affect the repolarization reserve of a patient, such as D85N in KCNE1.[5]

Classification

Congenital

The condition is inherited as a monogenic disorder with primarily autosomal dominant inheritance and variable penetrance. Multiple genetic mutations have been identified as the cause of LQTS.[3] [4] [5] [6]

- LQT1 is due to mutations in the KCNQ1 gene.

- LQT2 is due to mutations in the KCNH2 gene.
- LQT3 is due to mutations in the SCN5A gene.
- LQT4 to LQT17 have been described but are responsible for <10% of cases; affected genes include CALM1/2/3, TRDN, KCNE1/2, KCNJ2, and CACNA1C.

While 17 genes have been implicated in causing LQTS, some have limited or disputed evidence casting doubt on their association with disease.[7]

Inherited as either an autosomal dominant or a recessive trait, LQTS can be phenotypically classified into several congenital syndromes.

- Romano-Ward syndrome is inherited as an autosomal dominant trait. It may result from a mutation in any one of the identified genes and is not associated with deafness.[8]
- Jervell and Lange-Nielsen syndrome is inherited as an autosomal recessive trait and results from a homozygous mutation in KCNQ1. It is clinically characterized by a very severe form of LQTS and sensorineural deafness,[9] and those affected may experience their first cardiac event during infancy. This is much rarer than the Romano-Ward (autosomal dominant) pattern.
- Andersen-Tawil syndrome, also known as hypokalemic periodic paralysis or LQT7, is a rare autosomal dominant condition resulting from a mutation in the KCNJ2 gene.[5] These patients have periodic paralysis and ventricular tachyarrhythmias, and have a variety of dysmorphic features.[10]
- Timothy syndrome (LQTS8), a rare autosomal dominant syndrome associated with syndactyly, cardiac malformations, autism, and dysmorphic features.[2]

Acquired

Many factors are associated with the development of a prolonged QT interval:

- Drugs
- Electrolyte imbalances
- Bradyarrhythmias
- CNS lesions
- Malnutrition
- Pathologic genetic variants in KCNE1 and KCNE2.[5]

Case history

Case history #1

A 14-year-old girl, with a history of spells involving loss of consciousness, currently on antiepileptic drugs for a diagnosis of seizure disorder, presents to her pediatrician concerned about recurrent "seizures" despite taking her medication.

Case history #2

An 18-year-old, previously healthy, female college student suddenly collapses while rushing to class on a cold winter morning. Bystanders find her unresponsive and pulseless with agonal breathing. CPR is immediately commenced and emergency medical services are called.

Other presentations

The condition may also be discovered as an incidental ECG finding during the routine investigation of an unrelated presenting complaint. For example, a patient referred to a cardiologist with a concern of a heart murmur, determined to be an innocent flow murmur, may have an initial ECG revealing a prolonged corrected QT interval (QTc) of 0.49 seconds, suggesting the presence of LQTS.

Approach

The diagnosis of LQTS is not straightforward, as nearly 2.5% of the normal population may have a mildly prolonged QT interval, and nearly 25% of patients genotypically positive for LQTS may have normal-appearing QT intervals.[31] The QT interval is affected by heart rate (the slower the heart rate the longer the QT interval); therefore, rate-corrected QT interval (QTc) is used. Patients with LQTS may be risk-stratified for the probability of a future cardiac event (syncope, cardiac arrest, or sudden death) according to genotype, sex, age, and length of the QTc. It is also important to take into consideration any history of past symptoms when assessing the patient's risk of a future cardiac event. A careful history can help elucidate the presence of LQTS and identify its genetic subtype in the congenital form of the condition, or highlight the cause of QT interval prolongation in acquired LQTS. An ECG should be undertaken in all suspected cases.

The Schwartz criteria, based on ECG findings (length of corrected QT interval [QTc], presence of torsades de pointes, visible T-wave alternans, presence of notched T waves, low heart rate for age in children), clinical history (presence of syncope, congenital deafness), and family history (of LQTS or sudden death) can be used to aid the diagnosis of LQTS.[32] [33]

Presenting features

LQTS commonly presents in young people with cardiac arrest or unexplained syncope and is frequently misdiagnosed as epilepsy. It should therefore be considered in all such presentations, and a thorough history, including a review of premonitory symptoms and a corroborative history, is essential as it can help differentiate between cardiac syncope, epilepsy, and other causes of syncope, some of which may be benign conditions.

Cardiac syncope is characterized by premonitory symptoms such as palpitations, chest pain, and dyspnea. During the syncopal episode, pallor and cyanosis are common features, and the recovery period is brief and characterized by flushing.

In a patient with documented LQTS and syncope, it is important to try to identify triggers for syncope, as this may suggest a certain subtype of the syndrome.

- Patients with LQT1 typically have events (i.e., syncope or sudden death) during heightened adrenergic tone such as in exercise, particularly swimming.[34]
- Patients with LQT2 commonly have events during arousal or when startled, as by a telephone or alarm clock.[34]
- Female patients with LQTS are more prone to developing arrhythmic symptoms during the first 9 postpartum months, particularly patients with LQT2.[35]
- Patients with LQT3 commonly have events at rest and during bradycardia.[34]

Both congenital and acquired LQTS may present with palpitations secondary to premature ventricular complex and tachyarrhythmias including torsades de pointes, although the more common symptom is syncope (or cardiac arrest).

Acquired LQTS secondary to electrolyte imbalance may present with associated symptoms of hypokalemia, hypomagnesemia, and/or hypocalcemia.

- Hypokalemia is normally asymptomatic, but it may cause muscle weakness if severe.

- Hypomagnesemia may present with muscle weakness secondary to associated hypokalemia, as well as tetany (manifested as carpopedal spasm) and numbness (periorally and in the extremities) secondary to associated hypocalcemia.

Complete atrioventricular (AV) block may present with palpitations, syncope or presyncope, angina, and symptoms of reduced cardiac output (cold and clammy extremities, fatigue, listlessness, poor effort tolerance, dizziness, oliguria).

LQTS may also be discovered as an incidental ECG finding during the routine investigation of an unrelated presenting complaint such as a cardiac murmur, or during genetic diagnostic testing for another condition.[36]

Medication history

Drugs known to prolong the QT interval or cause depletion of potassium and/or magnesium may precipitate symptoms in patients with congenital LQTS or be the primary cause of acquired LQTS:

- Quinidine, procainamide, sotalol, amiodarone, disopyramide, dofetilide, phenothiazines, tricyclic antidepressants, and methadone.[21] [22] [Credible Meds (Arizona CERT): drugs that prolong the QT interval] (https://crediblemeds.org/index.php/login/dlcheck)
- Certain cancer treatments are also known to cause QT prolongation, e.g., kinase inhibitors, growth factor inhibitors, androgen-deprivation therapies, and chimeric antigen receptor T-cell therapies.[23] [24]

Medical history

Some medical conditions are known to cause acquired LQTS:

- Any sudden bradycardia or AV nodal block may result in QT prolongation or pause-dependent QT prolongation.
- Central nervous system lesions, such as intracranial hemorrhage (especially subarachnoid hemorrhage) and ischemic strokes.

Knowledge of the patient's medical history may also be helpful in identifying possible therapeutic drugs known to prolong the QT interval that the patient may be taking.

Family history

Review of the family history is extremely important to assist in making the diagnosis when it is in doubt, understand the penetrance of the condition, and screen, treat, and potentially avert cardiac arrest in family members.

If possible, the ECGs and medical records of all family members should be reviewed.

On occasion, a family member may have more pathologic findings than the affected proband; more commonly, the proband is the most severely involved.

Developing a family pedigree may help in discovering other affected but undiagnosed family members.

There may be a family history of complete AV block, which may indicate a diagnosis of acquired LQTS secondary to this condition.

Physical exam

Patients with Jervell and Lange-Nielsen syndrome have a very severe form of LQTS associated with sensorineural deafness.[9]

Patients with Andersen-Tawil syndrome have periodic paralysis (transient paralysis involving any part of the body and lasting seconds to hours, typically resolving spontaneously and sometimes associated with confusion and altered mental status) and ventricular tachyarrhythmias, and have a variety of dysmorphic features including micrognathia, low-set ears, widely spaced eyes, clinodactyly, syndactyly, and scoliosis.[10]

Severe hypokalemia may cause muscle weakness.

Patients with hypocalcemia may have positive Chvostek sign (twitching of facial muscles in response to tapping the facial nerve in the area of the parotid gland) and Trousseau sign (carpopedal spasm in response to inflation of a blood pressure (BP) cuff creating pressure in the upper limb greater than systolic BP).

Signs of reduced cardiac output (cold, clammy, pale, or cyanosed extremities; hypotension; confusion) may be present in complete AV block.

Schwartz criteria

The Schwartz criteria are diagnostic criteria for LQTS and are distinct from the criteria used to risk-stratify patients with known LQTS. Points are assigned to ECG, clinical, and familial findings. Patients with 3.5 or more points have a high probability of having LQTS, those with 1.5 to 3 points have an intermediate probability, and those with 1 or no points have a low probability of having LQTS.[32][33]

ECG findings (in the absence of medications or disorders known to affect these features)

- Corrected QT interval (QTc), defined as QT interval (in seconds) divided by the square root of the RR interval (in seconds):
    - ≥480 ms = 3 points
    - 460-479 ms = 2 points
    - 450-459 ms (in males) = 1 point.
- QTc 4th minute of recovery from exercise stress test ≥480 ms = 1 point
- Torsades de pointes = 2 points
- Visible T-wave alternans = 1 point
- Notched T wave in 3 leads = 1 point
- Low heart rate for age (resting heart rate below the 2nd percentile for age) = 0.5 points.

Clinical history

- Syncope (cannot receive points for both syncope and torsades de pointes)
    - With stress = 2 points
    - Without stress = 1 point.
- Congenital deafness = 0.5 points.

Family history (the same family member cannot be counted for LQTS and sudden death)

- Family members with definite LQTS = 1 point
- Unexplained sudden cardiac death under age 30 years among immediate family = 0.5 points.

Resting ECG

A resting ECG is crucial in the diagnosis of LQTS and should be undertaken in all suspected cases in order to confirm QT interval prolongation, help identify the LQTS subtype, and uncover any causative or contributory reversible factors. When measuring the QT interval, it may be helpful for the patient to move rapidly from lying to standing.[2]

In a patient with documented LQTS, it is very important to obtain ECGs from parents, siblings, and especially any family member with presyncope or syncope.

Careful attention must be given to the QT interval and the corrected QT interval (QTc). ECG findings associated with a high risk of life-threatening arrhythmias include T-wave alternans and functional 2:1 block.[5]



ECG showing QT prolongation (QTc = 519 ms)

Chong DW, Ankolekar SJ, McDonald J. BMJ Case Reports. 2009; doi:10.1136/bcr.01.2009.1426



ECG showing a corrected QTc interval of 760 ms

Iniesta I, Yotti R, Garcia-Pastor A. BMJ Case Reports. 2009; doi:10.1136/bcr.06.2008.0285

Inspection and appreciation of the T wave and whether it is monophasic or multiphasic may also be helpful.

- The QT interval is the ECG representation of ventricular depolarization and subsequent repolarization and may be measured in any lead in which it looks prolonged.



ECG showing QT prolongation (QTc = 519 ms)

Chong DW, Ankolekar SJ, McDonald J. BMJ Case Reports. 2009; doi:10.1136/bcr.01.2009.1426

- QT interval is measured using either tangent or threshold methods.The threshold method, measured from the onset of the initial wave of the QRS complex to where the T wave returns to the isoelectric baseline, has probably been the most commonly used.[1] [37] In the tangent method, the downslope of the T wave is extrapolated to the isoelectric baseline and this intersection is used for the end of the T wave. One study comparing the two methods found that the tangent method resulted in shorter QT intervals than the threshold method, and both methods were found to have high validity and diagnostic accuracy; however, the two methods need different cut-off values for use in practice.[38]
- The QT interval can also be measured with digital recordings using on screen calipers. Automated QT intervals are typically longer than manual measurements in lead II or V5 since they use the earliest lead for QRS onset and the latest lead for T-wave offset.[1] Some computerized ECG systems allow visualization of the automated QT interval (and other interval) measurements so they can be verified.
- The most commonly used formula to calculate the QTc is Bazett's formula: QT divided by the square root of the RR interval, where all intervals must be in seconds. The RR interval is the interval between each QRS complex, and should ideally be that immediately preceding the QT interval and averaged for 3 to 5 complexes. Sinus arrhythmia may lead to overestimation (or underestimation) of the QTc with 3 or even 5 complexes, so a broader average RR interval may be used in such cases.



ECG showing a corrected QTc interval of 760 ms

Iniesta I, Yotti R, Garcia-Pastor A. BMJ Case Reports. 2009; doi:10.1136/bcr.06.2008.0285

- Attention must be given to convert all measurements to seconds, otherwise the QTc measurement will be erroneous and meaningless. Online calculators are now available.

Each subtype of LQTS shows different characteristic ECG changes, although these are not universally present.

- LQT1 is characterized by prolonged QT intervals associated with a broad-based T wave.[16]



ECG findings in type 1 long QT syndrome

From the collection of Dr James P. Daubert

- LQT2 is characterized by low-amplitude and notched T waves.[16]



ECG findings in type 2 long QT syndrome

From the collection of Dr James P. Daubert

- LQT3 is characterized by long ST segments with a late-appearing T wave resulting in a long QT interval.[16]



ECG findings in type 3 long QT syndrome

From the collection of Dr James P. Daubert

Complete AV block, which can result in prolongation of the QT interval, or pause-dependent QT prolongation, resulting in acquired LQTS, show characteristic ECG changes:

- Sinus rhythm with normal atrial rate (represented by P-wave rate)
- No relationship between P waves and QRS complexes
- Widening of the QRS complex
- Ventricular rate (represented by QRS complex rate) <50 bpm.

Electrolyte abnormalities associated with acquired LQTS show characteristic ECG changes.

- Hypokalemia is characterized by ST depression, flattened T waves, prominent U waves, and a prolonged QT interval.
- Hypomagnesemia in itself does not have well-defined ECG abnormalities but, as it is often associated with hypokalemia and hypocalcemia, ECG changes associated with these may be present.
- Hypocalcemia causes isolated prolongation of the QT interval.

Serum electrolyte measurement

Hypokalemia, hypomagnesemia, and hypocalcemia may precipitate symptoms in patients with unrecognized congenital LQTS or be the primary cause of acquired LQTS. Serum electrolytes should therefore be measured in all patients found to have a prolonged QT interval on ECG.

Holter monitor

All patients with suspected or confirmed congenital LQTS should undergo Holter monitoring, the main purpose of which is to evaluate the behavior of the QT interval during:

- Bradycardia (at night)
- Tachycardia
- Sudden pauses (e.g., postextrasystolic).

Marked changes in QT morphology during the above changes in heart rate aid diagnosis.[39]

Holter monitoring may also allow the clinician to identify nonsustained ventricular arrhythmias in patients with LQTS who are asymptomatic, thereby assisting the decision-making process as to whether medical and/or device therapy should be initiated. A Holter monitor-derived "QT clock" may be used to improve detection of QT prolongation.[39]

Exercise tolerance testing

All patients with suspected or confirmed congenital LQTS should undergo an exercise tolerance test to identify abnormal QT interval prolongation during exercise and recovery, which is helpful in:

- Diagnosing LQTS, especially LQT1, in which the QT interval and QTc increase more than those of the controls or LQT2 and LQT3 patients
- Diagnosing LQTS when the QT interval is borderline prolonged
- Assisting in the prescription of a maximum exercise level for patients presenting with exercise-induced symptoms of presyncope or syncope, by simulating similar circumstances in a controlled environment.

Echocardiography

Echocardiography is helpful to assess for and rule out regional wall motion abnormalities suggestive of myocardial scarring or infarction. It is also helpful in ruling out and characterizing valvular stenotic or regurgitant lesions.

This investigation should be carried out in patients with suspected structural heart disease as suggested by a history of coronary artery disease, myocardial infarction, or valvular heart disease requiring surgical correction. SCN5A mutations in LQT3 may also exhibit cardiomyopathy.[40]

Genetic testing

Determination of the patient's genotype is recommended for all patients with a high probability of congenital LQTS (Schwartz score ≥3.5).[5] [41] For patients with an intermediate probability of congenital LQTS (Schwartz score 1.5 to 3), testing of established genes may be considered, mainly to help rule out a diagnosis.[5] Definitive disease-associated genes are currently KCNQ1, KCNH2, SCN5A, and CALM 1, 2, and 3; in patients with a high probability of congenital LQTS, CACNA1C and KCNE1 may also be considered.[5] For patients with defined syndromes, specific genes should be tested, for example KCNQ1 and KCNE1 in Jervell and Lange-Nielsen syndrome, or CACNA1C in Timothy syndrome.[5]

The identification of specific gene mutations enables:[5]

- Pinpointing of the exact channelopathy responsible for the LQTS, thus identifying the subtype
- Risk stratification of patients with congenital LQTS
- Mapping of the mutation's inheritance so that family members can be screened
- Initiation of gene-specific prophylactic treatment.

Genetic testing has a sensitivity of approximately 70% to 85% in index cases.[2] [5] It requires expert interpretation, and can be costly.[5] [42] In the absence of a family history of LQTS, it is not indicated for asymptomatic individuals with borderline QTc intervals (<480 ms). However, genetic testing is indicated when there is a very strong clinical diagnosis or when the QTc exceeds 500 ms on serial ECGs and a reversible cause is absent.[5] [42]

Certain genetic subtypes are associated with particularly severe phenotypes that have a higher incidence of sudden cardiac death (such as KCNQ1-A341V or SCN5A-G1631D), whereas others are associated with milder disease.[5] Patients with multiple LQTS gene mutations are at higher risk for breakthrough cardiac events during follow-up.[43] Family members should have variant-specific genetic testing once a disease-causing variant has been identified in an index case. Early identification of affected family members is important, even in those with a normal baseline QTc, and genetic testing can be carried out in children from birth.[2] [5]

In patients with acquired LQTS, genetic testing for defined disease-associated genes should be offered to those who experienced drug-induced torsades de pointes, are ages <40 years, and have a QTc interval >440 ms (males) and >450 ms (females) in the absence of the likely causative drug.[5] In these patients, a variant can be identified in >60% of cases.[5] Family screening is recommended for patients where a QT-prolonging drug is prescribed or being considered.[5]

European Society of Cardiology guidelines recommend that a diagnosis of LQTS is made in the presence of a pathogenic mutation, regardless of QT interval.[2]

Epinephrine test

This test involves a catecholamine challenge with a brief infusion of epinephrine and must be performed with immediate access to advanced life support and external defibrillation. It is not recommended by European guidelines due to low reproducibility.[2] However, it may be helpful in the diagnosis of LQT1 in which the QT interval and QTc increase more than those of the controls or LQT2 and LQT3 patients.[44]

Electrophysiology study

Investigating for inducible ventricular arrhythmias using electrophysiology studies has not been shown to have significant value in the diagnosis, treatment, or risk stratification of patients with LQTS.[2]

History and exam

Key diagnostic factors

history of known gene mutation (common)

- Includes KCNQ1 gene mutations, KCNH2 gene mutations, SCN5A gene mutations, and CALM gene mutations.

use of drugs or circumstances known to increase the QT interval (common)

- Some of the drugs known to prolong the QT interval or cause depletion of potassium and/or magnesium are quinidine, procainamide, sotalol, amiodarone, disopyramide, dofetilide, phenothiazines, tricyclic antidepressants, and methadone.[21] [22] [Credible Meds (Arizona CERT): drugs that prolong the QT interval] (https://crediblemeds.org/index.php/login/dlcheck) Certain cancer treatments are also known to cause QT prolongation, e.g., kinase inhibitors, growth factor inhibitors, androgen-deprivation therapies, and chimeric antigen receptor T-cell therapies.[23] [24]
- Electrolyte imbalances and bradyarrhythmias may result in QT prolongation.

syncope during heightened adrenergic tones (common)

- Patients with LQT1 typically have cardiac events during exercise, particularly swimming.

syncope during arousal or surprise (common)

- Patients with LQT2 commonly have cardiac events during arousal or when startled, as by a telephone or alarm clock.

arrhythmic symptoms postpartum (common)

- Female patients with LQT2 are more prone to developing arrhythmic symptoms during the first 9 postpartum months.[35]

syncope at rest and during bradycardia (common)

- Patients with LQT3 commonly have cardiac events at rest and during bradycardia.

cardiac syncope (common)

- Normally secondary to ventricular tachyarrhythmias or bradyarrhythmias.
- Characterized by premonitory symptoms such as palpitations, chest pain, and dyspnea. During the syncopal episode, pallor and cyanosis are common features, and the recovery period is brief and characterized by flushing.
- Complete atrioventricular block may present with cardiac syncope.

palpitations (common)

- Congenital and acquired LQTS may present with palpitations secondary to premature ventricular complex and tachyarrhythmias including torsades de pointes.

periodic paralysis (uncommon)

- Patients with Andersen-Tawil syndrome have periodic paralysis (transient paralysis involving any part of the body and lasting seconds to hours, typically resolving spontaneously and sometimes associated with confusion and altered mental status).

dysmorphic features (uncommon)

- Patients with Andersen-Tawil syndrome have a variety of dysmorphic features[10] including micrognathia, low-set ears, widely spaced eyes, clinodactyly, syndactyly, and scoliosis. The very rare Timothy syndrome (LQT8) can include dysmorphic features such as small upper jaw, low set ears, flattened nasal bridge, and cutaneous syndactyly.

sensorineural deafness (uncommon)

- Jervell and Lange-Nielsen syndrome is a very severe form of LQTS associated with sensorineural deafness.[9]

Other diagnostic factors

dizziness (common)

- Consequence of poor cerebral perfusion due to reduced cardiac output in complete atrioventricular block and transient ventricular tachyarrhythmias or torsades de pointes.

angina (uncommon)

- Potential symptom of complete atrioventricular block.

fatigue (uncommon)

- Fatigue, listlessness, and poor effort tolerance are symptoms of reduced cardiac output in complete atrioventricular block.

oliguria (uncommon)

- Consequence of poor renal perfusion due to reduced cardiac output in complete atrioventricular block.

muscle weakness (uncommon)

- Although hypokalemia is normally asymptomatic, it may cause muscle weakness if severe.

tetany (uncommon)

- Hypocalcemia causes tetany, which manifests as carpopedal spasm.

numbness (uncommon)

- Hypocalcemia causes numbness periorally and in the extremities.

Chvostek's sign (uncommon)

- Twitching of facial muscles in response to tapping the facial nerve in the area of the parotid gland, elicited in hypocalcemia.

Trousseau's sign (uncommon)

- Carpopedal spasm in response to inflation of a blood pressure (BP) cuff creating pressure in the upper limb greater than systolic BP, elicited in hypocalcemia.

cold and pale extremities (uncommon)

- Signs of reduced cardiac output secondary to compensatory peripheral vasoconstriction may be present in complete atrioventricular block.
- Extremities may be cyanosed and clammy.

hypotension (uncommon)

- Sign of reduced cardiac output in complete atrioventricular block.

confusion (uncommon)

- Consequence of poor cerebral perfusion due to reduced cardiac output in complete atrioventricular block.

Risk factors

Strong

KCNQ1 gene mutations

- LQT1 arises from mutations in the KCNQ1 gene. KCNQ1 mutations are the most commonly identified in genotyped patients. A homozygous mutation in KCNQ1 results in the autosomal recessive Jervell and Lange-Nielsen syndrome.[16]

KCNH2 gene mutations

- LQT2 arises from mutations in the KCNH2 gene. KCNH2 mutations are the second most commonly identified, accounting for up to 35% to 45% of genotyped patients.[16]

SCN5A gene mutations

- LQT3 arises from mutations in the SCN5A gene.[16]

QT interval-prolonging drugs

- Ingestion of drugs known to prolong the QT interval is a recognized risk factor in the development of acquired LQTS, and may reveal subclinical congenital LQTS.[27]
- Some of the drugs known to prolong the QT interval or cause depletion of potassium and/or magnesium include quinidine, procainamide, sotalol, amiodarone, disopyramide, dofetilide, phenothiazines, tricyclic antidepressants, and methadone.[21] [22] [Credible Meds (Arizona CERT): drugs that prolong the QT interval] (https://crediblemeds.org/index.php/login/dlcheck) Certain cancer treatments are also known to cause QT prolongation, e.g., kinase inhibitors, growth factor inhibitors, androgen-deprivation therapies, and chimeric antigen receptor T-cell therapies.[23] [24]

hypokalemia

- Hypokalemia causes hyperpolarization of myocardial cell membranes with consequent prolongation of repolarization, thus prolonging the QT interval.

hypomagnesemia

- Hypomagnesemia causes early afterdepolarizations, which in turn lead to prolonged repolarization of myocardial cells, thus prolonging the QT interval.

hypocalcemia

- Hypocalcemia prolongs the plateau phase of the action potential, thereby prolonging repolarization of myocardial cells, thus prolonging the QT interval.

bradyarrhythmias

- Any sudden bradycardia or atrioventricular nodal block may result in QT prolongation or pause-dependent QT prolongation.

central nervous system lesions

- Lesions such as intracranial hemorrhage (especially subarachnoid hemorrhage) and ischemic strokes.

Weak

female sex

- LQTS is more commonly diagnosed in women, which may be a spurious observation resulting from the higher upper limit for the corrected QT interval (QTc) in postpubertal females than in males (460 ms and 450 ms, respectively), although one report suggests a slightly higher incidence in females on the basis of genetics.[15]
- In early childhood, boys with LQT1 are more likely to experience syncope or sudden death, but boys are less likely than girls to have symptoms later in life.[8] [28]
- Women with LQT2 appear to be at higher risk of cardiac arrest, syncope, and/or sudden death than men and remain at risk into adulthood.[29] [30]
- Number of overall deaths is greater in women than in men.[28]

malnutrition

- Starvation and a liquid protein diet are known triggers of a prolonged QT interval.

Investigations

1st test to order

Test	Result
ECG for LQT1 • Resting ECG for LQT1.  *ECG findings in type 1 long QT syndrome* *From the collection of Dr James P. Daubert* • Should be undertaken in all suspected cases.[16] • QT interval and corrected QT interval (QTc) should be assessed. • T-wave morphology (monophasic or multiphasic) should be assessed. • QT interval is measured using either tangent or threshold methods. • QTc calculated using Bazett's formula: QT divided by the square root of the RR interval, where the RR interval is the interval between each QRS complex (ideally that immediately preceding the QT interval and averaged for 3 to 5 complexes). • All measurements in seconds.	**prolonged QT intervals associated with a broad-based T wave**
ECG for LQT2 • Resting ECG for LQT2.	**low-amplitude and notched T waves**

Test	Result
 *ECG findings in type 2 long QT syndrome* *From the collection of Dr James P. Daubert* • Should be undertaken in all suspected cases.[16] • QT interval and QTc should be assessed. • T-wave morphology (monophasic or multiphasic) should be assessed. • QT interval is measured using either tangent or threshold methods. • QTc calculated using Bazett's formula: QT divided by the square root of the RR interval, where the RR interval is the interval between each QRS complex (ideally that immediately preceding the QT interval and averaged for 3 to 5 complexes). • All measurements in seconds.	
ECG for LQT3 • Resting ECG for LQT3.  *ECG findings in type 3 long QT syndrome* *From the collection of Dr James P. Daubert* • Should be undertaken in all suspected cases.[16] • QT interval and QTc should be assessed. • T-wave morphology (monophasic or multiphasic) should be assessed. • QT interval is measured using either tangent or threshold methods. • QTc calculated using Bazett's formula: QT divided by the square root of the RR interval, where the RR interval is the interval between each QRS complex (ideally that immediately preceding the QT interval and averaged for 3 to 5 complexes). • All measurements in seconds.	**long ST segments with a late-appearing T wave resulting in a long QT interval**

Test	Result
ECG for hypokalemia and hypomagnesemia • Hypokalemia is a known cause of acquired LQTS. • Should be undertaken in all suspected cases. • QT interval and QTc should be assessed. • T-wave morphology (monophasic or multiphasic) should be assessed. • QT interval is measured using either tangent or threshold methods. • QTc calculated using Bazett's formula: QT divided by the square root of the RR interval, where the RR interval is the interval between each QRS complex (ideally that immediately preceding the QT interval and averaged for 3 to 5 complexes). • All measurements in seconds.	**ST depression, flattened T waves, prominent U waves, and prolonged QT interval in hypokalemia; ECG changes of coexisting hypokalemia in hypomagnesemia**
ECG for hypocalcemia • Hypocalcemia is a known cause of acquired LQTS. • Should be undertaken in all suspected cases. • QT interval and QTc should be assessed. • T-wave morphology (monophasic or multiphasic) should be assessed. • QT interval is measured using either tangent or threshold methods. • QTc calculated using Bazett's formula: QT divided by the square root of the RR interval, where the RR interval is the interval between each QRS complex (ideally that immediately preceding the QT interval and averaged for 3 to 5 complexes). • All measurements in seconds.	**isolated prolongation of the QT interval**
ECG for complete atrioventricular (AV) block • AV nodal block may result in QT prolongation or pause-dependent QT prolongation.	**sinus rhythm with normal atrial rate (represented by P-wave rate), no relationship between P waves and QRS complexes, widening of QRS complex, ventricular rate (represented by QRS complex rate) <50 bpm**
serum potassium • Hypokalemia may precipitate symptoms in patients with unrecognized congenital LQTS or be the primary cause of acquired LQTS.	**hypokalemia**
serum magnesium • Hypomagnesemia may precipitate symptoms in patients with unrecognized congenital LQTS or be the primary cause of acquired LQTS.	**hypomagnesemia**
serum calcium • Hypocalcemia may precipitate symptoms in patients with unrecognized congenital LQTS or be the primary cause of acquired LQTS.	**hypocalcemia**

Other tests to consider

Test	Result
Holter monitor • To evaluate the behavior of the QT interval during bradycardia (at night), tachycardia, or sudden pauses (e.g., postextrasystolic). • To identify nonsustained ventricular arrhythmias in asymptomatic patients with LQTS. • A Holter monitor-derived "QT clock" may be used to improve detection of QT prolongation.[39]	**intermittent QT and corrected QT interval prolongation associated with ventricular arrhythmias**
exercise tolerance test • Especially useful in the diagnosis of LQT1. • QT and corrected QT interval increase more in LQT1 than in LQT2 and LQT3. • Useful for diagnosis when the QT interval is borderline prolonged. • Assists in the prescription of a maximum exercise level for patients presenting with exercise-induced symptoms of presyncope or syncope.	**QT and corrected QT interval prolongation**
echocardiography • To assess for and rule out regional wall motion abnormalities suggestive of myocardial scarring or infarction. • Helpful in ruling out and characterizing valvular stenotic or regurgitant lesions.	**assessment of regional wall motion and valve function**
genetic testing • Pinpoints the channelopathy responsible for the LQTS, thus identifying the subtype.[41] • Aids risk stratification of patients. • Allows mapping of the mutation's inheritance so family members can be screened. • Relatively low sensitivity of approximately 70%, requires expert interpretation, and is very costly.[5] [42] In the absence of a family history of LQTS, it is not indicated for asymptomatic individuals with borderline QTc intervals (<480 ms). However, genetic testing is indicated when there is a very strong clinical diagnosis or when the QTc exceeds 500 ms on serial ECGs and a reversible cause is absent.[5] [42] • Patients with multiple LQTS gene mutations are at higher risk for breakthrough cardiac events during follow-up.[43]	**mutations in the KCNQ1 gene in LQT1, mutations in the KCNH2 gene in LQT2, mutations in the SCN5A gene in LQT3**
epinephrine test • Must be performed with immediate access to advanced life support and external defibrillation. • Especially useful in the diagnosis of LQT1.	**QT and corrected QT interval prolongation**

Differentials

Condition	Differentiating signs / symptoms	Differentiating tests
Acquired structural heart disease	• History of coronary artery disease (CAD), myocardial infarction (MI), or valvular heart disease requiring surgical correction.	• Echocardiographic changes consistent with CAD, previous MI, and valvular heart disease. Echocardiography may show regional left ventricular wall motion abnormalities suggestive of infarction and/or scarring. Valvular lesions such as regurgitant and/or stenotic valves in combination with left ventricular dysfunction may be identified by echocardiography. • ECG changes consistent with previous MI characterized by presence of Q waves.
Neurocardiogenic (vasovagal) syncope	• Triggers include cough, micturition, defecation, swallowing, upright posture, prolonged standing, heat, and hunger. • Premonitory symptoms include sweating, feeling hot, and nausea. • Recovery period: nausea and vomiting. • BP measurement may show orthostatic hypotension, particularly when provoked during a tilt table test.	• ECG shows normal QT interval.
Neurologic syncope	• Triggers include anxiety and stress in panic attack; fatigue, stress, and missed meals in migraine. • Premonitory symptoms include hyperventilation, paresthesiae in fingers and lips in panic attack; headache, visual disturbance, sensitivity to light and sound in migraine.	• ECG shows normal QT interval.
Catecholaminergic polymorphic ventricular tachyarrhythmias	• No differentiating signs or symptoms. • History extremely similar to that of LQTS, with arrhythmias triggered	• ECG is unremarkable at rest, with no significant prolongation of QT interval. • Exercise test provokes premature ventricular

Condition	Differentiating signs / symptoms	Differentiating tests
	by physical activity and emotional stress.	contractions with bidirectional ventricular tachyarrhythmias on ECG. • Genetic testing shows mutations in the RyR2 gene in autosomal dominant inheritance and mutations in the CASQ2 gene in autosomal recessive inheritance.
Epilepsy	• Triggers include inadequate sleep, alcohol, photic stimulation, drugs. • Premonitory symptoms: aura. • Syncopal episode: convulsive movement, tongue biting, and incontinence. • Recovery period: prolonged postictal state.	• EEG shows epileptiform abnormalities. • ECG shows normal QT interval.

Criteria

Schwartz criteria (1993-2012 LQTS diagnostic criteria)[32][33]

The Schwartz criteria are diagnostic criteria for LQTS and are distinct from the criteria used to risk-stratify patients with known LQTS.

Points are assigned to ECG, clinical, and familial findings. Patients with 3.5 or more points have a high probability of having LQTS, those with 1.5 or 3 points have an intermediate probability, and those with 1 or no points have a low probability of having LQTS.

ECG findings (in the absence of medications or disorders known to affect these features)

- Corrected QT interval (QTc), defined as QT interval (in seconds) divided by the square root of the RR interval (in seconds):
  - ≥480 ms = 3 points
  - 460-479 ms = 2 points
  - 450-459 ms (in males) = 1 point
- QTc 4th minute of recovery from exercise stress test ≥480 ms = 1 point
- Torsades de pointes = 2 points
- Visible T-wave alternans = 1 point
- Notched T wave in 3 leads = 1 point
- Low heart rate for age (resting heart rate below the 2nd percentile for age) = 0.5 points.

Clinical history

- Syncope (cannot receive points for both syncope and torsades de pointes)
    - With stress = 2 points
    - Without stress = 1 point.
- Congenital deafness = 0.5 points.

Family history (the same family member cannot be counted for LQTS and sudden death)

- Family members with definite LQTS = 1 point
- Unexplained sudden cardiac death under age 30 years among immediate family = 0.5 points.

Screening

Prenatal screening

Fetal genetic screening may allow determination of the presence of a given mutation, although the phenotypic penetrance of the mutation in utero cannot be determined solely on the basis of the genotype. Fetal genetic screening is not performed in routine clinical practice.

12-lead ECG

Although not universally implemented, in parts of Italy infants and young athletes are screened by ECG for LQTS.[45] [46]

Models using a 12-lead ECG to screen newborns for LQTS have been developed that appear to be cost-effective and successful in improving survival.[47]

In the US, there is no screening program of asymptomatic people for LQTS.

Approach

Given the increasing prevalence of LQTS and the associated risk of sudden cardiac death, primary care providers are likely to find themselves encountering challenging management decisions.

The mainstay of treatment for LQTS, unless there is an identifiable reversible cause, is lifestyle modification and beta-blocker therapy with the implantation of a cardioverter-defibrillator (ICD) in patients who have had a previous cardiac arrest and in those continuing to have symptoms despite beta-blockade.

Acquired LQTS

In acquired LQTS, management involves thorough assessment in order to identify and remove or treat the causative factor.

- Drug history should be taken to identify and remove drugs known to prolong the QT interval or cause depletion of potassium and/or magnesium, including quinidine, procainamide, sotalol, amiodarone, disopyramide, dofetilide, phenothiazines, tricyclic antidepressants, and methadone.[21] [22] [Credible Meds (Arizona CERT): drugs that prolong the QT interval] (https://crediblemeds.org/index.php/login/dlcheck)
- Serum electrolytes should be measured and corrected, in cases of hypokalemia, hypomagnesemia, and hypocalcemia; the goals of therapy include achieving a “high normal” potassium (of at least 4.0 to 4.5 mEq).
- Follow-up serial, periodic ECG monitoring is recommended until the QT interval has normalized.
- Any sudden bradycardia or atrioventricular (AV) nodal block may result in QT prolongation or pause-dependent QT prolongation. If an identifiable cause is not present, treatment involves implantation of a pacemaker (temporarily if the bradycardia or AV block improves, permanently if symptomatic bradycardia or AV block persists).
- Beta-blocker therapy, and lifestyle modification with avoidance of any further QT-prolonging drugs and monitoring, are indicated if removal of the causative drug is not possible due to medical necessity.
- Prophylactic treatment with beta-blockers and lifestyle modification are not indicated in these patients if the QT-prolonging agent is identified and removed.
- Cardiac events may include syncope, ventricular tachyarrhythmias, torsades de pointes, or cardiac arrest. For details of management, see Sustained ventricular tachycardias and Cardiac arrest .

Some patients with acquired LQTS may ultimately be diagnosed with congenital LQTS, and they should be managed as other patients with congenital LQTS (e.g., with beta-blockers, lifestyle modifications, and consideration of ICD).

Congenital LQTS without previous cardiac event

Treatment of congenital LQTS in patients without a previous cardiac event (e.g., syncope, ventricular tachyarrhythmias, torsades de pointes, or cardiac arrest) is dependent on whether the patient is at low- or high-risk of events.

Low risk (probability of first cardiac event before age 40 of <49%) is defined as: men or women with LQT1 or LQT2 and QTc <500 ms; men with LQT3 and QTc <500 ms; women with LQT3 (irrespective of level of QTc prolongation).

High risk (probability of first cardiac event 50% or higher) is defined as: men or women with LQT1 or LQT2 and QTc ≥500 ms; men with LQT3 and QTc ≥500 ms.[29]

The 1-2-3 LQTS risk calculator is an alternative risk stratification tool that estimates the 5-year risk of life-threatening arrhythmias for patients with LQTS based on QT interval and genotype; it may assist in the identification of patients who would benefit from ICD placement.[2] [48]

Low risk:

- Lifestyle modification and monitoring
    - Patients with LQT1 are at increased risk with activities that increase sympathetic activation, such as swimming, emotional stress, and exercise; they should avoid swimming unless cleared by LQTS experts, and should avoid extreme exertion until under optimal therapy and fully counseled.[5]
    - Patients with LQT2 are at high risk if woken from sleep or disturbed by a sudden noise.[5] Removal of alarm clocks and telephones from bedrooms is recommended.[5]
    - In general, competitive sports or similar extreme exertion should be avoided by patients with LQTS. However, patients who wish to engage in competitive sports should be referred for expert evaluation for risk stratification.[3] In one retrospective analysis of a cohort of patients with genotype-positive LQTS who were treatment-adherent, their participation in competitive or recreational sports was not associated with cardiac events or death.[49] Activities that are of low risk include golf, curling, cricket, billiards, or bowling.[50] Noncompetitive swimming, especially for LQT1 patients, must be limited and, if performed, should be done under close supervision. Selected low-risk patients without a history of exercise-induced symptoms may be considered for sports participation in consultation with an expert in LQTS and with careful education and consideration of options.[51]
    - All patients must avoid other sympathomimetics and factors that may prolong the QT interval, such as drugs including quinidine, procainamide, sotalol, amiodarone, disopyramide, dofetilide, phenothiazines, tricyclic antidepressants, and methadone.[21] [22] [Credible Meds (Arizona CERT): drugs that prolong the QT interval] (https://crediblemeds.org/index.php/login/dlcheck) Consult a drug formulary for a full list of drugs that prolong the QT interval.
    - Electrolyte loss due to vomiting, diarrhea, or excessive sweating should be replaced with electrolyte solutions in order to avoid hypokalemia and hypomagnesemia. Patients with LQT2 particularly require adequate potassium levels, and oral supplementation may be beneficial.[5]
- Beta-blockers
    - The mainstay of medical treatment for patients with congenital LQTS is beta-blocker therapy, ideally nonselective beta-blockers (e.g., nadolol, propranolol).[2] As ventricular arrhythmias may arise during a state of high adrenergic tone, particularly increasing the occurrence of afterdepolarizations, beta-blockers are used to blunt adrenergic stimulation.
    - Beta-blockers themselves will not shorten the QT interval, but their use is thought to prevent ventricular tachyarrhythmias, although they may provide less protection to patients with LQT3. Data from one study show that beta-blocker therapy reduces the risk of life-threatening cardiac events in females with LQT3; however, efficacy in males could not be determined conclusively because of the low number of events.[52]

- The efficacy of beta-blocker therapy may be assessed with exercise tolerance testing to ensure the heart rate response is blunted.
- Although no randomized controlled trials exist, observational data suggest a strong mortality benefit with beta-blocker therapy.[28] [53]
- Beta-blocker therapy should also be considered in patients with a normal QTc interval in the presence of a pathogenic mutation.[2]

High risk:

- Lifestyle modification and monitoring: the recommendations are the same as for low-risk patients.
- Beta-blockers: the recommendations are the same as for low-risk patients.
- Implantable cardioverter-defibrillator (ICD): in Jervell and Lange-Nielsen syndrome and in certain very high-risk patients with LQT1, LQT2, or LQT3, ICD can be considered but expert consultation should be sought first.[2] This should include a discussion regarding the risks of not having an ICD and the advantages/disadvantages of an ICD, single- or dual-chamber depending on the individual patient and following specialist cardiologist or electrophysiologist advice.
- Mexiletine: should be considered in patients with confirmed LQT3, especially those with syncope or ICD shocks despite beta-blocker therapy; use in other genotypes is being investigated.[5] [54] [55] Oral testing should be carried out to ensure that the QTc is shortened by at least 40ms before prescribing mexiletine long term.[2] There is currently no evidence on whether mexiletine should be given alone or in combination with beta-blocker therapy for patients with LQT3.[2]
- Left cardiac sympathetic denervation: may be considered in patients with recurrent syncope despite treatment with beta-blockers or in those requiring multiple appropriate ICD shocks.[2] It may also be an option in patients who are deemed not to be ideal candidates for an ICD, such as children, due to the physical limitations of age and height and the psychologic distress of ICD shocks.

Congenital LQTS with previous cardiac event

Cardiac events may include syncope, ventricular tachyarrhythmias, torsades de pointes, or cardiac arrest. For details of management, see Sustained ventricular tachycardias and Cardiac arrest .

Lifestyle modification

- Required in all patients with congenital LQTS; the recommendations are the same as for patients without a previous cardiac event.

Beta-blocker therapy

- Required in all patients with congenital LQTS; the recommendations are the same as for patients without a previous cardiac event.

Implantable cardioverter-defibrillator (ICD)

- Use of an ICD, in conjunction with beta-blockers, has proven invaluable in the treatment of patients with LQTS who have recurrent arrhythmic syncope or documented torsades de pointes despite optimally dosed beta-blocker therapy.[2] [56] [57]
- ICDs are now considered appropriate therapy for:
  - Patients who have had a previous cardiac arrest.[2]

- Those with recurrent arrhythmic syncope despite beta-blocker therapy, or in those whom beta-blocker therapy is contraindicated or not tolerated.[2]
- Some patients with high-risk LQTS, especially patients with LQT2 or those with multiple mutations.[58]
- Jervell and Lange-Nielsen syndrome.

Mexiletine

- Should be considered in patients with confirmed LQT3, especially those with syncope or ICD shocks despite beta-blocker therapy; use in other genotypes is being investigated.[2] [5] [54] [55]

Left cardiac sympathetic denervation

- Sometimes called stellate ganglionectomy, this procedure involves surgical resection of the lower half of the left stellate ganglion along with several other thoracic ganglia (T2 to T4) in an attempt to partially denervate the heart.[59]
- This procedure is available at specialized medical centers and referral should be considered for:
  - Patients who cannot tolerate beta-blockers or in whom beta-blockers are contraindicated[2]
  - Those with recurrent arrhythmic syncope despite beta-blocker therapy[2]
  - Patients receiving multiple ICD shocks[2]
  - Patients in whom ICD implantation is contraindicated or declined[2]
  - Children in whom an ICD, due to the physical limitations of age and height and the psychological distress of ICD shocks, is not appropriate.
  - Jervell and Lange-Nielsen syndrome.
- Development of a minimally invasive thoracoscopic approach makes left cardiac sympathetic denervation a more attractive option for these patients. Left cardiac sympathetic denervation is well tolerated and does not negatively affect cardiovascular performance.[2] Side effects may occur with this treatment though, and breakthrough events occur in half of the patients after the procedure.[2] [60]

Permanent pacemaker

- When combined with beta-blockers, atrial (or, less optimally, ventricular) pacing, which prevents bradycardia, may facilitate the uptitration of beta-blockers to more effective antiarrhythmic doses and can also serve to prevent pause-dependent torsades de pointes.[61]
- A permanent pacemaker in conjunction with beta-blocker therapy should be considered if:
  - The patient continues to have symptoms despite a left cardiac sympathetic denervation
  - There is a lack of surgical experience in thoracoscopic left cardiac sympathetic denervation (and the patient declines referral to a specialized center).
- However, no randomized study exists comparing the efficacy of pacemakers combined with beta-blockers versus ICDs in preventing symptoms in patients with LQTS. Pacemakers are infrequently used in LQTS given the similar risks of indwelling leads that an ICD system has and lack of back-up defibrillation.

Treatment algorithm overview

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer

Acute (summary)		
acquired LQTS		
	1st	removal or treatment of causative factor(s)
	adjunct	beta-blocker, lifestyle modification, and monitoring
congenital LQTS without previous cardiac event		
■ low risk	1st	lifestyle modification and monitoring
	plus	beta-blocker
■ high risk	1st	lifestyle modification and monitoring
	plus	beta-blocker
	adjunct	left cardiac sympathetic denervation
	adjunct	implantable cardioverter-defibrillator (ICD)
	adjunct	mexiletine
congenital LQTS with previous cardiac event		
	1st	beta-blocker
	plus	lifestyle modification and monitoring
	adjunct	implantable cardioverter-defibrillator (ICD)
	adjunct	mexiletine
	2nd	left cardiac sympathetic denervation
	plus	continue beta-blocker, lifestyle modification, and monitoring
	3rd	permanent pacemaker
	plus	continue beta-blocker, lifestyle modification, and monitoring

Treatment algorithm

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer

Acute

acquired LQTS

1st **removal or treatment of causative factor(s)**

» In acquired LQTS, management involves thorough assessment in order to identify and remove or treat the causative factor.

» Take a drug history to identify and remove drugs known to prolong the QT interval or cause depletion of potassium and/or magnesium.[21] [22] [Credible Meds (Arizona CERT): drugs that prolong the QT interval] (https://crediblemeds.org/index.php/login/dlcheck) Consult a drug formulary for a full list of drugs that prolong the QT interval.

» Measure serum electrolytes and correct hypokalemia, hypomagnesemia, and hypocalcemia; the goals of therapy include achieving a "high normal" potassium (of at least 4.0 to 4.5 mEq).

» Follow-up serial, periodic ECG monitoring until QT interval has normalized.

» Any sudden bradycardia or atrioventricular (AV) nodal block may result in QT prolongation or pause-dependent QT prolongation. If an identifiable cause is not present, treatment involves implantation of a pacemaker (temporary if the bradycardia or AV block improves, permanent if symptomatic bradycardia or AV block persists).

» Prophylactic treatment with beta-blockers and lifestyle modification are not indicated in these patients if the QT-prolonging agent is identified and removed.

» Cardiac events may include syncope, ventricular tachyarrhythmias, torsades de pointes, or cardiac arrest. For details of management, see Sustained ventricular tachycardias and Cardiac arrest .

adjunct **beta-blocker, lifestyle modification, and monitoring**

Treatment recommended for SOME patients in selected patient group

Primary options

MANAGEMENT

Acute

» nadolol: adults: 40 mg orally once daily initially, increase according to response, maximum 320 mg/day

OR

» propranolol hydrochloride: neonates: consult specialist for guidance on dose; children: 1 mg/kg/day orally (immediate-release) given in 3 divided doses initially, increase according to response, maximum 8 mg/kg/day; adults: 30-160 mg/day orally (immediate-release) given in 3 divided doses

» Beta-blockers and lifestyle modifications may be indicated if removal of the causative drug is not possible due to medical necessity.

» Ideally nonselective beta-blockers (e.g., nadolol, propranolol) are used.[2]

» As ventricular arrhythmias may arise during a state of high adrenergic tone, particularly increasing the occurrence of afterdepolarizations, beta-blockers are used to blunt adrenergic stimulation. Beta-blockers themselves do not shorten the QT interval, but their use is thought to prevent ventricular tachyarrhythmias.

» Low-dose beta-blockers are prescribed initially and titrated up as tolerated.

» Dose adjustments may be required to avoid symptomatic bradycardia.

» Electrolyte loss due to vomiting, diarrhea, or excessive sweating should be replaced with electrolyte solutions.

» Sympathomimetics, factors that may prolong the QT interval, and startling acoustic stimulation such as alarm clocks should be avoided.

» Generally, competitive sports and extreme exertion should be avoided. However, patients who wish to engage in competitive sports should be referred for expert evaluation for risk stratification.[3] Selected low-risk patients without a history of exercise-induced symptoms may be considered for sports participation in consultation with an expert in LQTS and with careful education and consideration of options.[51]

» ECG should be monitored annually or biannually and after initiation or adjustment of beta-blocker therapy (if applicable).

Acute

» Exercise testing and/or Holter monitoring should be carried out to confirm adequate beta-blockade after the initiation of beta-blockers, assess ongoing adequacy of beta-blockade, and augment dosage as necessary in children undergoing somatic growth (if applicable).

» Measure serum electrolytes to monitor for hypokalemia, hypomagnesemia, and hypocalcemia.

» Review medication for drugs contraindicated in LQTS.

» Consult a drug formulary for a full list of drugs that prolong the QT interval.

» Take symptom history for detection of interim syncope.

congenital LQTS without previous cardiac event

low risk — **1st** — **lifestyle modification and monitoring**

» Cardiac events may include syncope, ventricular tachyarrhythmias, torsades de pointes, or cardiac arrest.

» Low risk: corrected QT interval (QTc) <500 ms in men or women with LQT1 and LQT2, women with LQT3.

» Electrolyte loss due to vomiting, diarrhea, or excessive sweating should be replaced with electrolyte solutions. Patients with LQT2 particularly require adequate potassium levels, and oral supplementation may be beneficial.[5]

» Sympathomimetics, factors that may prolong the QT interval, and startling acoustic stimulation such as alarm clocks should be avoided (especially for LQT2 patients).

» Generally, competitive sports and extreme exertion should be avoided, and noncompetitive swimming (especially for LQT1 patients) should be limited and done under close supervision. However, patients who wish to engage in competitive sports should be referred for expert evaluation for risk stratification.[3] Selected low-risk patients without a history of exercise-induced symptoms may be considered for sports participation in consultation with an expert in LQTS and with careful education and consideration of options.[51]

Acute

» ECG should be monitored annually or biannually and after initiation or adjustment of beta-blocker therapy (if applicable).

» Exercise testing and/or Holter monitoring should be carried out to confirm adequate beta-blockade after the initiation of beta-blockers (if applicable), assess ongoing adequacy of beta-blockade, and augment dosage as necessary in children undergoing somatic growth (if applicable).

» Measure serum electrolytes to monitor for hypokalemia, hypomagnesemia, and hypocalcemia.

» Review medication for drugs contraindicated in LQTS.

» Consult a drug formulary for a full list of drugs that prolong the QT interval.

» Take symptom history for detection of interim syncope.

plus **beta-blocker**

Treatment recommended for ALL patients in selected patient group

Primary options

» nadolol: adults: 40 mg orally once daily initially, increase according to response, maximum 320 mg/day

OR

» propranolol hydrochloride: neonates: consult specialist for guidance on dose; children: 1 mg/kg/day orally (immediate-release) given in 3 divided doses initially, increase according to response, maximum 8 mg/kg/day; adults: 30-160 mg/day orally (immediate-release) given in 3 divided doses

» Cardiac events may include syncope, ventricular tachyarrhythmias, torsades de pointes, or cardiac arrest.

» The mainstay of medical treatment for all patients with LQTS is beta-blocker therapy, ideally nonselective beta-blockers (e.g., nadolol, propranolol).[2] As ventricular arrhythmias may arise during a state of high adrenergic tone, particularly increasing the occurrence of afterdepolarizations, beta-blockers are used to blunt adrenergic stimulation. Beta-blockers themselves do not shorten the QT interval,

Acute

but their use is thought to prevent ventricular tachyarrhythmias.

» Low risk: corrected QT interval (QTc) <500 ms in men or women with LQT1 and LQT2, women with LQT3.

» There is some debate concerning the administration of beta-blockers to patients with LQT3 verified by genotyping. Data from one study show that beta-blocker therapy reduces the risk of life-threatening cardiac events in females with LQT3; however, efficacy in males could not be determined conclusively because of the low number of events.[52]

» Beta-blocker therapy should also be considered in patients with a normal QTc interval in the presence of a pathogenic mutation.[2]

» Low-dose beta-blockers are prescribed initially and titrated up as tolerated.

» Dose adjustments may be required to avoid symptomatic bradycardia.

high risk **1st** **lifestyle modification and monitoring**

» Cardiac events may include syncope, ventricular tachyarrhythmias, torsades de pointes, or cardiac arrest.

» High risk: corrected QT interval (QTc) >500 ms in men or women with LQT1 and LQT2 and in men with LQT3, and QTc >550 ms.

» Electrolyte loss due to vomiting, diarrhea, or excessive sweating should be replaced with electrolyte solutions. Patients with LQT2 particularly require adequate potassium levels, and oral supplementation may be beneficial.[5]

» Sympathomimetics, factors that may prolong the QT interval, and startling acoustic stimulation such as alarm clocks should be avoided (especially for LQT2 patients).

» Generally, competitive sports and extreme exertion should be avoided, and noncompetitive swimming (especially for LQT1 patients) should be limited and done under close supervision. However, patients who wish to engage in competitive sports should be referred for expert evaluation for risk stratification.[3]

» ECG should be monitored annually or biannually and after initiation or adjustment of beta-blocker therapy (if applicable).

Acute

» Exercise testing and/or Holter monitoring should be carried out to confirm adequate beta-blockade after the initiation of beta-blockers (if applicable), assess ongoing adequacy of beta-blockade, and augment dosage as necessary in children undergoing somatic growth (if applicable).

» Measure serum electrolytes to monitor for hypokalemia, hypomagnesemia, and hypocalcemia.

» Review medication for drugs contraindicated in LQTS.

» Consult a drug formulary for a full list of drugs that prolong the QT interval.

» Take symptom history for detection of interim syncope.

plus **beta-blocker**

Treatment recommended for ALL patients in selected patient group

Primary options

» nadolol: adults: 40 mg orally once daily initially, increase according to response, maximum 320 mg/day

OR

» propranolol hydrochloride: neonates: consult specialist for guidance on dose; children: 1 mg/kg/day orally (immediate-release) given in 3 divided doses initially, increase according to response, maximum 8 mg/kg/day; adults: 30-160 mg/day orally (immediate-release) given in 3 divided doses

» Cardiac events may include syncope, ventricular tachyarrhythmias, torsades de pointes, or cardiac arrest. The mainstay of medical treatment for all patients with LQTS is beta-blocker therapy, ideally nonselective beta-blockers (e.g., nadolol, propranolol).[2]

» As ventricular arrhythmias may arise during a state of high adrenergic tone, particularly increasing the occurrence of afterdepolarizations, beta-blockers are used to blunt adrenergic stimulation. Beta-blockers themselves do not shorten the QT interval, but their use is thought to prevent ventricular tachyarrhythmias.

Acute

» High risk: corrected QT interval (QTc) >500 ms in men or women with LQT1 and LQT2 and in men with LQT3 and QTc >550 ms.

» There is some debate concerning the administration of beta-blockers to patients with LQT3 verified by genotyping. Data from one study show that beta-blocker therapy reduces the risk of life-threatening cardiac events in females with LQT3; however, efficacy in males could not be determined conclusively because of the low number of events.[52]

» Low-dose beta-blockers are prescribed initially and titrated up as tolerated.

» Dose adjustments may be required to avoid symptomatic bradycardia.

adjunct **left cardiac sympathetic denervation**

Treatment recommended for SOME patients in selected patient group

» May be considered in patients with recurrent syncope despite treatment with beta-blockers or in those requiring multiple appropriate ICD shocks. It may also be an option in patients who are deemed not to be ideal candidates for an ICD, such as children, due to the physical limitations of age and height and the psychologic distress of ICD shocks.

adjunct **implantable cardioverter-defibrillator (ICD)**

Treatment recommended for SOME patients in selected patient group

» Cardiac events may include syncope, ventricular tachyarrhythmias, torsades de pointes, or cardiac arrest.

» In Jervell and Lange-Nielsen syndrome patients, and in certain very high-risk patients with LQT1, LQT2, or LQT3, ICD can be considered but expert consultation should be sought first.[2] This should include a discussion with the patient regarding the risks of not having an ICD and the advantages and disadvantages of an ICD.

» Single- or dual-chamber depending on the individual patient and following specialist (cardiologist or electrophysiologist) advice.

adjunct **mexiletine**

Treatment recommended for SOME patients in selected patient group

Primary options

Acute

» mexiletine: consult specialist for guidance on dose

» Should be considered in patients with confirmed LQT3, especially those with syncope or ICD shocks despite beta-blocker therapy; use in other genotypes is being investigated.[5] [54] [55]

» Oral testing should be carried out to ensure that the QTc is shortened by at least 40 ms before prescribing mexiletine long term.[2] There is currently no evidence on whether mexiletine should be given alone or in combination with beta-blocker therapy for patients with LQT3.[2]

congenital LQTS with previous cardiac event

1st **beta-blocker**

Primary options

» nadolol: adults: 40 mg orally once daily initially, increase according to response, maximum 320 mg/day

OR

» propranolol hydrochloride: neonates: consult specialist for guidance on dose; children: 1 mg/kg/day orally (immediate-release) given in 3 divided doses initially, increase according to response, maximum 8 mg/kg/day; adults: 30-160 mg/day orally (immediate-release) given in 3 divided doses

» Cardiac events may include syncope, ventricular tachyarrhythmias, torsades de pointes, or cardiac arrest.

» The mainstay of medical treatment for all patients with LQTS is beta-blocker therapy, ideally nonselective beta-blockers (e.g., nadolol, propranolol).[2] As ventricular arrhythmias may arise during a state of high adrenergic tone, particularly increasing the occurrence of afterdepolarizations, beta-blockers are used to blunt adrenergic stimulation. Beta-blockers themselves do not shorten the QT interval, but their use is thought to prevent ventricular tachyarrhythmias.

» Low-dose beta-blockers are prescribed initially and titrated up as tolerated.

» Dose adjustments may be required to avoid symptomatic bradycardia.

Acute

plus **lifestyle modification and monitoring**

Treatment recommended for ALL patients in selected patient group

» Cardiac events may include syncope, ventricular tachyarrhythmias, torsades de pointes, or cardiac arrest.

» Electrolyte loss due to vomiting, diarrhea, or excessive sweating should be replaced with electrolyte solutions. Patients with LQT2 particularly require adequate potassium levels, and oral supplementation may be beneficial.[5]

» Sympathomimetics, factors that may prolong the QT interval, and startling acoustic stimulation such as alarm clocks should be avoided (especially for LQT2 patients).

» Generally, competitive sports and extreme exertion should be avoided, and noncompetitive swimming (especially for LQT1 patients) should be limited and done under close supervision. However, patients who wish to engage in competitive sports should be referred for expert evaluation for risk stratification.[3] Selected low-risk patients without a history of exercise-induced symptoms may be considered for sports participation in consultation with an expert in LQTS and with careful education and consideration of options.[51]

» ECG should be monitored annually or biannually and after initiation or adjustment of beta-blocker therapy (if applicable).

» Exercise testing and/or Holter monitoring should be carried out to confirm adequate beta-blockade after the initiation of beta-blockers (if applicable), assess ongoing adequacy of beta-blockade, and augment dosage as necessary in children undergoing somatic growth (if applicable).

» Measure serum electrolytes to monitor for hypokalemia, hypomagnesemia, and hypocalcemia.

» Review medication for drugs contraindicated in LQTS.

» Consult a drug formulary for a full list of drugs that prolong the QT interval.

» Take symptom history for detection of interim syncope.

adjunct **implantable cardioverter-defibrillator (ICD)**

Acute

Treatment recommended for SOME patients in selected patient group

» Use of an ICD, in conjunction with beta-blockers, has proven invaluable in the treatment of patients with LQTS who have recurrent arrhythmic syncope or documented torsades de pointes despite optimally dosed beta-blocker therapy.[2] [56] [57]

» Indications for an ICD include any of the following: previous ventricular tachyarrhythmias and/or torsades de pointes, previous cardiac arrest, persistent syncope, some patients with high-risk LQTS, especially patients with LQT2 or those with multiple mutations, contraindications or intolerance to beta-blockers.[2] [58]

» Single- or dual-chamber depending on the individual patient and following specialist (cardiologist or electrophysiologist) advice.

adjunct **mexiletine**

Treatment recommended for SOME patients in selected patient group

Primary options

» mexiletine: consult specialist for guidance on dose

» Should be considered in patients with confirmed LQT3, especially those with syncope or ICD shocks despite beta-blocker therapy; use in other genotypes is being investigated.[2] [5] [54] [55]

2nd **left cardiac sympathetic denervation**

» Sometimes called stellate ganglionectomy, this procedure involves surgical resection of the lower half of the left stellate ganglion along with several other thoracic ganglia (T2 to T4) in an attempt to partially denervate the heart.

» Indications include inadequate response to or not a candidate for implantable cardioverter-defibrillator (ICD), receipt of multiple ICD shocks, and children in whom an ICD is not appropriate due to the physical limitations of age and height and the psychological distress of ICD shocks.[2]

» A thoracoscopic left cardiac sympathetic denervation has been developed, and is now routinely done by experienced surgeons in specialized medical centers.

plus **continue beta-blocker, lifestyle modification, and monitoring**

Acute

Treatment recommended for ALL patients in selected patient group

» Beta-blocker therapy should be continued unless contraindicated or poorly tolerated.

3rd **permanent pacemaker**

» Indicated if symptoms continue despite sympathectomy.

» If there is a lack of surgical experience in thoracoscopic left cardiac sympathetic denervation (and the patient declines referral to a specialized center).

» Single- or dual-chamber depending on the individual patient and following specialist (cardiologist or electrophysiologist) advice.

plus **continue beta-blocker, lifestyle modification, and monitoring**

Treatment recommended for ALL patients in selected patient group

» Beta-blocker therapy should be continued unless contraindicated or poorly tolerated.

» When combined with beta-blockers, ventricular pacing, which prevents bradycardia, may facilitate the up-titration of beta-blockers to more effective anti-arrhythmic doses and can also serve to prevent pause-dependent torsades de pointes.[61]

Emerging

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators

Early data suggest that the cystic fibrosis drug lumacaftor/ivacaftor may be of clinical use in LQT2 patients through its action on the hERG (human ether-a-go-go) gene trafficking defect affecting potassium channels.[5]

Primary prevention

Because congenital LQTS is an inherited condition, primary prevention is not applicable. Early detection and treatment of hypokalemia and hypomagnesemia, and avoidance of drugs known to prolong the QT interval where possible, may prevent some cases of acquired LQTS.

Patients starting QT-prolonging anticancer therapy should have a baseline assessment for underlying risk factors and have their QT interval monitored before and during treatment.[23] [24]

Secondary prevention

Patients should be advised to avoid drugs known to have the potential to prolong the QT interval or cause depletion of potassium and/or magnesium, such as quinidine, procainamide, sotalol, amiodarone, disopyramide, dofetilide, phenothiazines, tricyclic antidepressants, and methadone.[21] [22] [Credible Meds (Arizona CERT): drugs that prolong the QT interval] (https://crediblemeds.org/index.php/login/dlcheck) Energy drinks that contain large amounts of caffeine may lead to QT prolongation and caution should be exercised in patients with LQTS.[63]

Patients with LQT2 should avoid startling acoustic stimulation such as alarm clocks. In general, competitive sports or similar extreme exertion should be avoided by patients with LQTS. However, patients who wish to engage in competitive sports should be referred for expert evaluation for risk stratification.[3]

Parental genetic counseling and testing prior to conception is recommended to determine the potential risk of having a child affected with LQTS.

In-vitro fertilization, with implantation of a fertilized oocyte confirmed to be free of the known mutation, may be an option for parents carrying an affected gene.

Patient discussions

Patients should be advised to:

- Avoid drugs known to have the potential to prolong the QT interval or cause depletion of potassium and/or magnesium, such as quinidine, procainamide, sotalol, amiodarone, disopyramide, dofetilide, phenothiazines, tricyclic antidepressants, and methadone.[21] [22] [Credible Meds (Arizona CERT): drugs that prolong the QT interval] (https://crediblemeds.org/index.php/login/dlcheck) Energy drinks that contain large amounts of caffeine may lead to QT prolongation and caution should be exercised in patients with LQTS.[63]
- Avoid alarm clocks or loud, unexpected noises (especially LQT2 patients)
- Avoid unsupervised swimming (especially LQT1 patients)
- Report any syncopal episodes immediately
- Replace electrolyte loss due to vomiting, diarrhea, or excessive sweating with electrolyte solutions.

FOLLOW UP

Monitoring

Monitoring

EGCs are undertaken routinely on an annual or biannual basis and after initiation or adjustment of beta-blocker therapy.

Exercise testing and/or Holter monitoring is done to confirm adequate beta-blockade after the initiation of beta-blockers, assess ongoing adequacy of beta-blockade, and augment dosage as necessary in children undergoing somatic growth.

Serum electrolyte measurement to monitor for hypokalemia, hypomagnesemia, and hypocalcemia.

Medication review for drugs contraindicated in LQTS, such as quinidine, procainamide, sotalol, amiodarone, disopyramide, dofetilide, phenothiazines, and tricyclic antidepressants. [Credible Meds (Arizona CERT): drugs that prolong the QT interval] (https://crediblemeds.org/index.php/login/dlcheck)

Symptom history for detection of interim syncope.

Consideration of genotyping to facilitate family evaluation, and confirmation of full evaluation of family.

Patients with LQTS who undergo general anesthesia require careful perioperative monitoring, as they are at high risk of torsades de pointes perioperatively. Little is known about the effects of LQTS during pregnancy, but the incidence of dysrhythmia increases postpartum, so careful monitoring of LQTS patients in the postpartum period is also required.[62]

Complications

Complications	Timeframe	Likelihood
torsades de pointes	**variable**	**medium**

A polymorphic ventricular tachyarrhythmias (VT) secondary to genetic mutations that lead to dysfunctional potassium channels and subsequent slowed repolarization and transmural dispersion of repolarization, which predisposes to VT.



Rhythm strips showing torsades de pointes
Chong DW, Ankolekar SJ, McDonald J. BMJ Case Reports. 2009; doi:10.1136/bcr.01.2009.1426

Treatment is with intravenous magnesium and electrical cardioversion.

Torsades de pointes with associated pause-dependent VT is additionally treated with temporary ventricular pacing or isoproterenol.

In addition, electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia) should be corrected, and drugs known to prolong the QT interval or cause depletion of potassium and/or magnesium should be discontinued.

cardiac arrest	**variable**	**low**

Secondary to polymorphic ventricular tachyarrhythmias degenerating into ventricular fibrillation.

Emergency treatment is with CPR and defibrillation as per the adult advanced life support protocol.

In addition, electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia) should be corrected, and drugs known to prolong the QT interval or cause depletion of potassium and/or magnesium, such as quinidine, procainamide, sotalol, amiodarone, disopyramide, dofetilide, phenothiazines, and tricyclic antidepressants, should be discontinued. [Credible Meds (Arizona CERT): drugs that prolong the QT interval] (https://crediblemeds.org/index.php/login/dlcheck)

FOLLOW UP

Complications	Timeframe	Likelihood
sudden cardiac death	**variable**	**low**
Secondary to cardiac arrest resulting from polymorphic ventricular tachyarrhythmias.		

Prognosis

Asymptomatic and undiagnosed

These patients may have normal life expectancy and may remain asymptomatic. Patients with congenital LQTS may pass on the specific mutation to their offspring, who may then become symptomatic. Prognosis is variable and depends on risk stratification for the probability of a future cardiac event (syncope, cardiac arrest, or sudden death), which in turn depends on the history of symptoms, genotype, sex, age, and length of the corrected QT interval (QTc).

Asymptomatic and diagnosed

These patients may have normal life expectancy and may remain asymptomatic. Treatment with beta-blockers may be considered if high-risk features are identified. Lifestyle modifications, especially in patients with congenital LQTS, should be emphasized and encouraged. These patients may progress to become symptomatic.[43]

Symptomatic with ≥1 syncopal episodes

These patients are at risk of recurrent syncopal episodes. Careful attention must be given to minimize all identifiable triggers that may prolong the QT interval, including drugs and electrolyte abnormalities. These patients benefit most from treatment with beta-blockers and an implantable cardioverter-defibrillator (ICD).

Symptomatic with cardiac arrest

These patients are at highest risk of recurrent episodes of syncope and/or cardiac arrest. Previous cardiac arrest carries a higher risk of LQTS-related sudden death. Careful attention must be given to minimize all identifiable triggers that may prolong the QT interval, including drugs and electrolyte abnormalities. Survival is enhanced with beta-blocker and ICD therapy.

Diagnostic guidelines

International

HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes (http://www.hrsonline.org/Policy-Payment/Clinical-Guidelines-Documents?SearchText=&seeall=1) [3]

Published by: Heart Rhythm Society; European Heart Rhythm Association; Asia Pacific Heart Rhythm Society

Last published: 2013

European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases (https://www.escardio.org/Guidelines/Scientific-Documents) [5]

Published by: European Heart Rhythm Association (EHRA)Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS)

Last published: 2022

2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death (https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines) [2]

Published by: European Society of Cardiology

Last published: 2022

Treatment guidelines

International

HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes (http://www.hrsonline.org/Practice-Guidance/Clinical-Guidelines-Documents?SearchText=&seeall=1) [3]

Published by: Heart Rhythm Society; European Heart Rhythm Association; Asia Pacific Heart Rhythm Society

Last published: 2013

2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death (https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines) [2]

Published by: European Society of Cardiology

Last published: 2022

2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death (http://professional.heart.org/professional/GuidelinesStatements/UCM_316885_Guidelines-Statements.jsp) [27]

Published by: American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines

Last published: 2018

Online resources

1. Credible Meds (Arizona CERT): drugs that prolong the QT interval (https://crediblemeds.org/index.php/login/dlcheck) *(external link)*

REFERENCES

Key articles

- Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126. Full text (https://www.doi.org/10.1093/eurheartj/ehac262) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/36017572?tool=bestpractice.bmj.com)
- Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013 Dec;10(12):1932-63. Full text (https://www.heartrhythmjournal.com/article/S1547-5271%2813%2900552-3/fulltext) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/24011539?tool=bestpractice.bmj.com)
- Wilde AAM, Semsarian C, Márquez MF, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus statement on the state of genetic testing for cardiac diseases. Europace. 2022 Sep 1;24(8):1307-67. Full text (https://www.doi.org/10.1093/europace/euac030) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/35373836?tool=bestpractice.bmj.com)
- Roden DM. Clinical practice. Long-QT syndrome. N Engl J Med. 2008 Jan 10;358(2):169-76. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/18184962?tool=bestpractice.bmj.com)
- Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e272-391. Full text (https://www.ahajournals.org/doi/10.1161/CIR.0000000000000549?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/29084731?tool=bestpractice.bmj.com)
- Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol. 2007 Jan 23;49(3):329-37. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/17239714?tool=bestpractice.bmj.com)
- Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993 Aug;88(2):782-4. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/8339437?tool=bestpractice.bmj.com)
- Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation. 2011 Nov 15;124(20):2181-4. Full text (https://www.doi.org/10.1161/CIRCULATIONAHA.111.062182) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/22083145?tool=bestpractice.bmj.com)

References

1. Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and

U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation. 2009 Mar 17;119(10):e241-50. Full text (https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.108.191096?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/19228821?tool=bestpractice.bmj.com)

2. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126. Full text (https://www.doi.org/10.1093/eurheartj/ehac262) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/36017572?tool=bestpractice.bmj.com)

3. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013 Dec;10(12):1932-63. Full text (https://www.heartrhythmjournal.com/article/S1547-5271%2813%2900552-3/fulltext) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/24011539?tool=bestpractice.bmj.com)

4. Wallace E, Howard L, Liu M, et al. Long QT syndrome: genetics and future perspective. Pediatr Cardiol. 2019 Oct;40(7):1419-30. Full text (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785594) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/31440766?tool=bestpractice.bmj.com)

5. Wilde AAM, Semsarian C, Márquez MF, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus statement on the state of genetic testing for cardiac diseases. Europace. 2022 Sep 1;24(8):1307-67. Full text (https://www.doi.org/10.1093/europace/euac030) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/35373836?tool=bestpractice.bmj.com)

6. Beckmann BM, Scheiper-Welling S, Wilde AAM, et al. Clinical utility gene card for: long-QT syndrome. Eur J Hum Genet. 2021 Dec;29(12):1825-32. Full text (https://www.doi.org/10.1038/s41431-021-00904-y) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/34031550?tool=bestpractice.bmj.com)

7. Adler A, Novelli V, Amin AS, et al. An international, multicentered, evidence-based reappraisal of genes reported to cause congenital long QT syndrome. Circulation. 2020 Feb 11;141(6):418-28. Full text (https://www.doi.org/10.1161/CIRCULATIONAHA.119.043132) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/31983240?tool=bestpractice.bmj.com)

8. Roden DM. Clinical practice. Long-QT syndrome. N Engl J Med. 2008 Jan 10;358(2):169-76. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/18184962?tool=bestpractice.bmj.com)

9. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 1957 Jul;54(1):59-68. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/13435203?tool=bestpractice.bmj.com)

REFERENCES

10. Plaster NM, Tawil R, Tristani-Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell. 2001 May 18;105(4):511-9. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/11371347?tool=bestpractice.bmj.com)

11. Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation. 2009 Nov 3;120(18):1761-7. Full text (https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.109.863209?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/19841298?tool=bestpractice.bmj.com)

12. Schwartz PJ, Priori SG, Napolitano C. How really rare are rare diseases?: The intriguing case of independent compound mutations in the long QT syndrome. J Cardiovasc Electrophysiol. 2003 Oct;14(10):1120-21. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/14521668?tool=bestpractice.bmj.com)

13. Modell SM, Lehmann MH. The long QT syndrome family of cardiac ion channelopathies: a HuGE review. Genet Med. 2006 Mar;8(3):143-55. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/16540748?tool=bestpractice.bmj.com)

14. Vincent GM. The long-QT syndrome - bedside to bench to bedside. N Engl J Med. 2003 May 8;348(19):1837-8. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/12736277?tool=bestpractice.bmj.com)

15. Imboden M, Swan H, Denjoy I, et al. Female predominance and transmission distortion in the long-QT syndrome. N Engl J Med. 2006 Dec 28;355(26):2744-51. Full text (http://www.nejm.org/doi/full/10.1056/NEJMoa042786#t=article) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/17192539?tool=bestpractice.bmj.com)

16. Moss AJ. Long QT syndrome. JAMA. 2003 Apr 23-30;289(16):2041-4. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/12709446?tool=bestpractice.bmj.com)

17. Yu H, Zhang L, Liu J, et al. Acquired long QT syndrome in hospitalized patients. Heart Rhythm. 2017 Jul;14(7):974-8. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/28323171?tool=bestpractice.bmj.com)

18. Lin Y, Yu H, Liu F, et al. Hospitalized cancer patients with acquired long QT syndrome-a matched case-control study. Cardiooncology. 2020;6:3. Full text (https://www.doi.org/10.1186/s40959-020-0057-2) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/32154029?tool=bestpractice.bmj.com)

19. Napolitano C, Priori SG, Schwartz PJ, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA. 2005 Dec 21;294(23):2975-80. Full text (https://jamanetwork.com/journals/jama/fullarticle/202046) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/16414944?tool=bestpractice.bmj.com)

20. Vincent GM. Long QT syndrome. Cardiol Clin. 2000 May;18(2):309-25. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/10849875?tool=bestpractice.bmj.com)

21. Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med. 2009 Mar 17;150(6):387-95. Full text (http://annals.org/aim/fullarticle/744382/qtc-interval-

screening-methadone-treatment) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/19153406?tool=bestpractice.bmj.com)

22. Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation. 2020 Oct 13;142(15):e214-33. Full text (https://www.ahajournals.org/doi/10.1161/CIR.0000000000000905?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/32929996?tool=bestpractice.bmj.com)

23. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229-361. Full text (https://www.doi.org/10.1093/eurheartj/ehac244) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/36017568?tool=bestpractice.bmj.com)

24. Giraud EL, Ferrier KRM, Lankheet NAG, et al. The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview. Lancet Oncol. 2022 Sep;23(9):e406-15. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/36055309?tool=bestpractice.bmj.com)

25. Dagradi F, Spazzolini C, Castelletti S, et al. Exercise training-induced repolarization abnormalities masquerading as congenital long QT syndrome. Circulation. 2020 Dec 22;142(25):2405-15. Full text (https://www.doi.org/10.1161/CIRCULATIONAHA.120.048916) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/33073610?tool=bestpractice.bmj.com)

26. El-Sherif N, Turitto G. Electrolyte disorders and arrhythmogenesis. Cardiol J. 2011;18(3):233-45. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/21660912?tool=bestpractice.bmj.com)

27. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e272-391. Full text (https://www.ahajournals.org/doi/10.1161/CIR.0000000000000549?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/29084731?tool=bestpractice.bmj.com)

28. Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol. 2007 Jan 23;49(3):329-37. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/17239714?tool=bestpractice.bmj.com)

29. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003 May 8;348(19):1866-74. Full text (http://www.nejm.org/doi/full/10.1056/NEJMoa022147#t=article) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/12736279?tool=bestpractice.bmj.com)

30. Migdalovich D, Moss AJ, Lopes CM, et al. Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome. Heart Rhythm. 2011 Oct;8(10):1537-43. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/21440677?tool=bestpractice.bmj.com)

REFERENCES

31. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011 Jan 4;57(1):51-9. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/21185501?tool=bestpractice.bmj.com)

32. Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993 Aug;88(2):782-4. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/8339437?tool=bestpractice.bmj.com)

33. Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation. 2011 Nov 15;124(20):2181-4. Full text (https://www.doi.org/10.1161/CIRCULATIONAHA.111.062182) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/22083145?tool=bestpractice.bmj.com)

34. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001 Jan 2;103(1):89-95. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/11136691?tool=bestpractice.bmj.com)

35. Seth R, Moss AJ, McNitt S, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007 Mar 13;49(10):1092-8. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/17349890?tool=bestpractice.bmj.com)

36. Landstrom AP, Chahal AA, Ackerman MJ, et al. Interpreting incidentally identified variants in genes associated with heritable cardiovascular disease: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2023 Apr;16(2):e000092. Full text (https://www.doi.org/10.1161/HCG.0000000000000092) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/36970980?tool=bestpractice.bmj.com)

37. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol. 2006 Mar;17(3):333-6. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/16643414?tool=bestpractice.bmj.com)

38. Vink AS, Neumann B, Lieve KVV, et al. Determination and interpretation of the QT interval. Circulation. 2018 Nov 20;138(21):2345-58. Full text (https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.033943?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/30571576?tool=bestpractice.bmj.com)

39. Page A, Aktas MK, Soyata T, et al. "QT clock" to improve detection of QT prolongation in long QT syndrome patients. Heart Rhythm. 2016 Jan;13(1):190-98. Full text (http://www.heartrhythmjournal.com/article/S1547-5271(15)01127-3/fulltext) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/26334569?tool=bestpractice.bmj.com)

40. Wilde AAM, Amin AS. Clinical spectrum of SCN5A mutations: long QT syndrome, Brugada syndrome, and cardiomyopathy. JACC Clin Electrophysiol. 2018 May;4(5):569-79. Full text (https://www.sciencedirect.com/science/article/pii/S2405500X18302081?via%3Dihub) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/29798782?tool=bestpractice.bmj.com)

41. Musunuru K, Hershberger RE, Day SM, et al. Genetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2020

Aug;13(4):e000067. Full text (https://www.ahajournals.org/doi/10.1161/HCG.0000000000000067?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/32698598?tool=bestpractice.bmj.com)

42. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011 Aug;8(8):1308-39. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/21787999?tool=bestpractice.bmj.com)

43. Rohatgi RK, Sugrue A, Bos JM, et al. Contemporary outcomes in patients with long QT syndrome. J Am Coll Cardiol. 2017 Jul 25;70(4):453-62. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/28728690?tool=bestpractice.bmj.com)

44. Vyas H, Hejlik J, Ackerman MJ. Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT response. Circulation. 2006 Mar 21;113(11):1385-92. Full text (http://circ.ahajournals.org/content/113/11/1385.full) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/16534005?tool=bestpractice.bmj.com)

45. Schwartz PJ. Pro: newborn ECG screening to prevent sudden cardiac death. Heart Rhythm. 2006 Nov;3(11):1353-5. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/17074644?tool=bestpractice.bmj.com)

46. Schwartz PJ, Stramba-Badiale M, Segantini A, et al. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med. 1998 Jun 11;338(24):1709-14. Full text (http://www.nejm.org/doi/full/10.1056/NEJM199806113382401#t=article) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/9624190?tool=bestpractice.bmj.com)

47. Quaglini S, Rognoni C, Spazzolini C, et al. Cost-effectiveness of neonatal ECG screening for the long QT syndrome. Eur Heart J. 2006 Aug;27(15):1824-32. Full text (https://academic.oup.com/eurheartj/article/27/15/1824/2887219) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/16840497?tool=bestpractice.bmj.com)

48. Mazzanti A, Trancuccio A, Kukavica D, et al. Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk). Europace. 2022 Apr 5;24(4):614-9. Full text (https://www.doi.org/10.1093/europace/euab238) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/34505884?tool=bestpractice.bmj.com)

49. Aziz PF, Sweeten T, Vogel RL, et al. Sports participation in genotype positive children with long QT syndrome. JACC Clin Electrophysiol. 2015 Mar-Apr;1(1-2):62-70. Full text (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540361) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/26301263?tool=bestpractice.bmj.com)

50. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation. 2004 Jun 8;109(22):2807-16. Full text (http://circ.ahajournals.org/content/109/22/2807.full) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/15184297?tool=bestpractice.bmj.com)

REFERENCES

51. Johnson JN, Ackerman MJ. Competitive sports participation in athletes with congenital long QT syndrome. JAMA. 2012 Aug 22;308(8):764-5. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/22820673?tool=bestpractice.bmj.com)

52. Wilde AA, Moss AJ, Kaufman ES, et al. Clinical aspects of type 3 long-QT syndrome: an international multicenter study. Circulation. 2016 Sep 20;134(12):872-82. Full text (https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.021823?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/27566755?tool=bestpractice.bmj.com)

53. Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA. 2006 Sep 13;296(10):1249-54. Full text (https://jamanetwork.com/journals/jama/fullarticle/203339) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/16968849?tool=bestpractice.bmj.com)

54. Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol. 2016 Mar 8;67(9):1053-8. Full text (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773513) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/26940925?tool=bestpractice.bmj.com)

55. Bos JM, Crotti L, Rohatgi RK, et al. Mexiletine shortens the QT interval in patients with potassium channel-mediated type 2 long QT syndrome. Circ Arrhythm Electrophysiol. 2019 May;12(5):e007280. Full text (https://www.ahajournals.org/doi/10.1161/CIRCEP.118.007280?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/31006312?tool=bestpractice.bmj.com)

56. Zareba W, Moss AJ, Daubert JP, et al. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003 Apr;14(4):337-41. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/12741701?tool=bestpractice.bmj.com)

57. Garratt CJ, Elliott P, Behr E, et al. Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes. Europace. 2010 Aug;12(8):1156-75. Full text (https://academic.oup.com/europace/article/12/8/1156/449311) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/20663787?tool=bestpractice.bmj.com)

58. Biton Y, Rosero S, Moss AJ, et al. Primary prevention with the implantable cardioverter-defibrillator in high-risk long-QT syndrome patients. Europace. 2019 Feb 1;21(2):339-46. Full text (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365807) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/29947754?tool=bestpractice.bmj.com)

59. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004 Apr 20;109(15):1826-33. Full text (http://circ.ahajournals.org/content/109/15/1826.full) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/15051644?tool=bestpractice.bmj.com)

60. Waddell-Smith KE, Ertresvaag KN, Li J, et al. Physical and psychological consequences of left cardiac sympathetic denervation in long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2015

Oct;8(5):1151-8. Full text (https://www.ahajournals.org/doi/10.1161/CIRCEP.115.003159?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/26224781?tool=bestpractice.bmj.com)

61. Viskin S. Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J Cardiovasc Electrophysiol. 2000 May;11(5):593-600. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/10826941?tool=bestpractice.bmj.com)

62. Drake E, Preston R, Douglas J. Brief review: anesthetic implications of long QT syndrome in pregnancy.Can J Anaesth. 2007 Jul;54(7):561-72. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/17602043?tool=bestpractice.bmj.com)

63. Shah SA, Szeto AH, Farewell R, et al. Impact of high volume energy drink consumption on electrocardiographic and blood pressure parameters: a randomized trial. J Am Heart Assoc. 2019 Jun 4;8(11):e01131 Full text (https://www.ahajournals.org/doi/10.1161/JAHA.118.011318?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/31137991?tool=bestpractice.bmj.com)

Images



Figure 1: ECG findings in type 1 long QT syndrome

From the collection of Dr James P. Daubert



Figure 2: ECG findings in type 2 long QT syndrome

From the collection of Dr James P. Daubert



Figure 3: ECG findings in type 3 long QT syndrome

From the collection of Dr James P. Daubert



Figure 4: ECG showing QT prolongation (QTc = 519 ms)

Chong DW, Ankolekar SJ, McDonald J. BMJ Case Reports. 2009; doi:10.1136/bcr.01.2009.1426

IMAGES



Figure 5: ECG showing a corrected QTc interval of 760 ms

Iniesta I, Yotti R, Garcia-Pastor A. BMJ Case Reports. 2009; doi:10.1136/bcr.06.2008.0285



Figure 6: ECG findings in type 1 long QT syndrome

From the collection of Dr James P. Daubert



Figure 7: ECG findings in type 2 long QT syndrome

From the collection of Dr James P. Daubert



Figure 8: ECG findings in type 3 long QT syndrome

From the collection of Dr James P. Daubert



Figure 9: Rhythm strips showing torsades de pointes

Chong DW, Ankolekar SJ, McDonald J. BMJ Case Reports. 2009; doi:10.1136/bcr.01.2009.1426

Disclaimer

BMJ Best Practice is intended for licensed medical professionals. BMJ Publishing Group Ltd (BMJ) does not advocate or endorse the use of any drug or therapy contained within this publication nor does it diagnose patients. As a medical professional you retain full responsibility for the care and treatment of your patients and you should use your own clinical judgement and expertise when using this product.

This content is not intended to cover all possible diagnosis methods, treatments, follow up, drugs and any contraindications or side effects. In addition, since such standards and practices in medicine change as new data become available, you should consult a variety of sources. We strongly recommend that you independently verify specified diagnosis, treatments and follow-up and ensure it is appropriate for your patient within your region. In addition, with respect to prescription medication, you are advised to check the product information sheet accompanying each drug to verify conditions of use and identify any changes in dosage schedule or contraindications, particularly if the drug to be administered is new, infrequently used, or has a narrow therapeutic range. You must always check that drugs referenced are licensed for the specified use and at the specified doses in your region.

Information included in BMJ Best Practice is provided on an “as is” basis without any representations, conditions or warranties that it is accurate and up to date. BMJ and its licensors and licensees assume no responsibility for any aspect of treatment administered to any patients with the aid of this information. To the fullest extent permitted by law, BMJ and its licensors and licensees shall not incur any liability, including without limitation, liability for damages, arising from the content. All conditions, warranties and other terms which might otherwise be implied by the law including, without limitation, the warranties of satisfactory quality, fitness for a particular purpose, use of reasonable care and skill and non-infringement of proprietary rights are excluded.

Where BMJ Best Practice has been translated into a language other than English, BMJ does not warrant the accuracy and reliability of the translations or the content provided by third parties (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages). BMJ is not responsible for any errors and omissions arising from translation and adaptation or otherwise.Where BMJ Best Practice lists drug names, it does so by recommended International Nonproprietary Names (rINNs) only. It is possible that certain drug formularies might refer to the same drugs using different names.

Please note that recommended formulations and doses may differ between drug databases drug names and brands, drug formularies, or locations. A local drug formulary should always be consulted for full prescribing information.

Treatment recommendations in BMJ Best Practice are specific to patient groups. Care is advised when selecting the integrated drug formulary as some treatment recommendations are for adults only, and external links to a paediatric formulary do not necessarily advocate use in children (and vice-versa). Always check that you have selected the correct drug formulary for your patient.

Where your version of BMJ Best Practice does not integrate with a local drug formulary, you should consult a local pharmaceutical database for comprehensive drug information including contraindications, drug interactions, and alternative dosing before prescribing.

Interpretation of numbers

Regardless of the language in which the content is displayed, numerals are displayed according to the original English-language numerical separator standard. For example 4 digit numbers shall not include a comma nor a decimal point; numbers of 5 or more digits shall include commas; and numbers stated to be less than 1 shall be depicted using decimal points. See Figure 1 below for an explanatory table.

BMJ accepts no responsibility for misinterpretation of numbers which comply with this stated numerical separator standard.

This approach is in line with the guidance of the International Bureau of Weights and Measures Service.

Figure 1 – BMJ Best Practice Numeral Style

5-digit numerals: 10,000

4-digit numerals: 1000

numerals < 1: 0.25

Our full website and application terms and conditions can be found here: Website Terms and Conditions.

Contact us

+ 44 (0) 207 111 1105
support@bmj.com

BMJ
BMA House
Tavistock Square
London
WC1H 9JR
UK

Contributors:

// Authors:

Mehmet K. Aktas, MD, MBA

Associate Professor of Medicine
University of Rochester Medical Center, Rochester, NY
DISCLOSURES: MKA declares that he has received research grants from Astra Zeneca, Medtronic, and Boston Scientific. MKA has served as consultant for Abbott and Huxley Medical. MKA holds a patent for "ECG Clock Electrocardiogram Based Diagnostic Device and Method" (US patent #10,085,667). He is the author of a reference cited in this topic.

James P. Daubert, MD

Professor of Medicine
Duke University Medical Center, Duke Clinical Research Institute, Durham, NC
DISCLOSURES: JPD declares that he has received honoraria for advisory boards, steering committees, data safety monitoring boards, events committees, and lecture fees from Abbott, Acutus Medical, Affera Inc., Biosense Webster, Biotronik, Boston Scientific, Farapulse, Gilead Sciences Inc., Medtronic, Microport, Phillips, and Vytronus; and research grants from Abbott, Biosense Webster, Boston Scientific, Farapulse, and Medtronic. He receives royalty payments from Wiley, Springboard and McGraw Hill for textbook authorship and educational materials. JPD declares that he has no stock, stock options, or other forms of ownership. He is the author of a reference cited in this topic.

// Peer Reviewers:

Sami Viskin, MD

Director of Cardiac Hospitalization
Department of Cardiology, Tel Aviv Medical Center, Tel Aviv, Israel
DISCLOSURES: SV declares that he has no competing interests.

Elizabeth S. Kaufman, MD

Associate Professor
Heart and Vascular Center, MetroHealth Campus, Case Western Reserve University, Cleveland, OH
DISCLOSURES: ESK declares that she has no competing interests.